Alvogen and Pfenex's PF708 (biosimilar- teriparatide) Receives FDA's Approval for the Treatment of Osteoporosis
Shots:
- The US FDA has granted approval to PF708- a biosimilar of Eli Lilly’s Forteo (teriparatide injection) under the 505(b)(2) regulatory pathway for the treatment of osteoporosis in certain patients at high risk for fracture
- Pfenex will receive a $2.5M milestone from Alvogen on its approval in the US. The PF708 is the first approved product of Pfenex- validating Pfenex Expression Technology platform and enhances patient’s access to a cost-effective alternative to Forteo
- Pfenex is conducting a comparative human factors study between PF708 and Forteo- evaluating the therapeutic equivalence of both the therapies with its anticipated submission by the end of Oct’19
Click here to read full press release/ article | Ref: PRNewswire | Image: Pfenex
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com